Der­maEXO kicks off at the Uni­ver­si­ty of Oulu

The offi­cial launch of Der­maEXO, a new Research to Busi­ness (R2B) project fund­ed by Busi­ness Fin­land has been announced. The project kick-off event was suc­cess­ful­ly orga­nized on 9 Jan­u­ary, mark­ing the start of a 21-month jour­ney run­ning from Jan­u­ary 2026 toward com­mer­cial­iz­ing a break­through diag­nos­tic plat­form for demen­tia.

Demen­tia rep­re­sents one of the most press­ing glob­al health­care chal­lenges of our time. As pop­u­la­tions age, the num­ber of peo­ple liv­ing with demen­tia con­tin­ues to rise, plac­ing an increas­ing bur­den on patients, fam­i­lies, care­givers, and health­care sys­tems. Despite major advances in neu­ro­science, today’s diag­nos­tic path­ways remain cost­ly, inva­sive, and often inac­ces­si­ble, rely­ing on lum­bar punc­tures, advanced imag­ing such as amy­loid-PET scans, and mul­ti­ple spe­cial­ist vis­its. Crit­i­cal­ly, many patients are diag­nosed too late, miss­ing the win­dow where emerg­ing ther­a­pies are most effec­tive.

Der­maEXO is poised to trans­form the land­scape of demen­tia diag­no­sis by devel­op­ing an inno­v­a­tive, nee­dle-free diag­nos­tic plat­form designed for the ear­ly detec­tion and dif­fer­en­ti­a­tion of demen­tia sub­types, includ­ing Alzheimer’s dis­ease and fron­totem­po­ral demen­tia. By inte­grat­ing advanced opti­cal imag­ing ana­lyt­ics with mol­e­c­u­lar bio­mark­er pro­fil­ing, Der­maEXO aims to iden­ti­fy dis­ease sig­na­tures well before the onset of severe symp­toms, there­by enhanc­ing the accu­ra­cy of diag­no­sis among var­i­ous demen­tia types. This pio­neer­ing approach seeks not only to facil­i­tate time­ly inter­ven­tions but also to improve patient out­comes through pre­cise clas­si­fi­ca­tion and under­stand­ing of the dis­ease.

Ear­ly pilot stud­ies asso­ci­at­ed with Der­maEXO have yield­ed promis­ing results and are cur­rent­ly pro­tect­ed by patent FI20253472. Addi­tion­al find­ings are in the process of sub­mis­sion, fur­ther strength­en­ing the pro­jec­t’s sci­en­tif­ic foun­da­tion. This intel­lec­tu­al prop­er­ty pro­tec­tion not only secures the inno­va­tions devel­oped but also posi­tions Der­maEXO for future com­mer­cial­iza­tion oppor­tu­ni­ties, paving the way for advance­ments in demen­tia diag­no­sis and treat­ment.

Beyond sci­en­tif­ic inno­va­tion, Der­maEXO is firm­ly ori­ent­ed toward mar­ket readi­ness. Over the 21-month project, the team will devel­op a reg­u­la­to­ry and com­mer­cial­iza­tion strat­e­gy, build strate­gic part­ner­ships with diag­nos­tic lab­o­ra­to­ries and health­care providers, and pre­pare for mar­ket entry through a lab­o­ra­to­ry-devel­oped test (LDT) mod­el. This approach enables faster adop­tion by lever­ag­ing exist­ing clin­i­cal infra­struc­ture while keep­ing reg­u­la­to­ry and oper­a­tional bar­ri­ers man­age­able in the ear­ly phas­es.

The mar­ket oppor­tu­ni­ty is sub­stan­tial. The glob­al demen­tia diag­nos­tics mar­ket is val­ued at over USD 7.5 bil­lion and is grow­ing rapid­ly, dri­ven by increas­ing aware­ness of cog­ni­tive health and the emer­gence of dis­ease-mod­i­fy­ing ther­a­pies that depend on ear­ly diag­no­sis. Non-inva­sive, cost-effec­tive screen­ing tools like Der­maEXO are well-posi­tioned to meet ris­ing demand from hos­pi­tals, mem­o­ry clin­ics, diag­nos­tic lab­o­ra­to­ries, and, in the future, even pri­ma­ry health­care and home-test­ing con­texts.

Look­ing ahead, DermaEXO’s scal­able plat­form also opens oppor­tu­ni­ties beyond demen­tia, with poten­tial appli­ca­tions in oth­er neu­ro­log­i­cal con­di­tions such as brain can­cer. By reduc­ing diag­nos­tic bur­den, improv­ing acces­si­bil­i­ty, and enabling ear­li­er inter­ven­tion, Der­maEXO has the poten­tial to deliv­er both sig­nif­i­cant health­care impact and long-term com­mer­cial val­ue.

With the sup­port of Busi­ness Fin­land and a strong trans­la­tion­al vision, Der­maEXO is now offi­cial­ly underway—bridging cut­ting-edge research and real-world health­care solu­tions.

Source (text and image): Der­maEXO

Image: Nsrein Ali and oth­er mem­bers of the Oys­ter team.